Aurora, CONCT05482321Now EnrollingIRB Ready

Type1diabetes Clinical Trial in Aurora, CO

Access cutting-edge type1diabetes treatment through this clinical trial at a research site in Aurora. Study-provided care at no cost to qualified participants.

Sponsored by University of Colorado, Denver

Quick Self-Assessment

See if you qualify for this Aurora location

Preparing your pre-screening questions…

Expert Care in Aurora

Access type1diabetes specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related type1diabetes treatment provided free

Apply for This Aurora Location

Check if you qualify for this type1diabetes clinical trial in Aurora, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Aurora

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Aurora site if eligible
  4. 4Begin participation

About This Type1diabetes Study in Aurora

The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the pancreas of human subjects. The investigators will then determine 1) whether these pancreas blood flow factors differ between healthy subjects and those who have recently developed type1 diabetes; and 2) how variable measurements are in healthy subjects and subjects that recently developed type1 diabetes, both between subjects and over time. To address these aims the investigators will perform pancreas ultrasound measurements in each subject using an approved injectable 'bubble' contrast agent that allows measurement of pancreas blood flow. The investigators will compare ultrasound measurement with characteristics of the subject's type 1 diabetes, including genetic factors, glucose levels and other circulating factors, as well as other factors that may influence blood flow in the pancreas independent of type1 diabetes. The successful conclusion of this study will indicate whether measuring pancreas blood flow speed/volume will be helpful in monitoring whether type1 diabetes will emerge and thus will allow a large scale study to answer this question.

Sponsor: University of Colorado, Denver

Who Can Participate

Inclusion Criteria

Male or non-pregnant female age 18-65
Ability and willingness of patient to participate fully in all aspects of this clinical study
Written informed consent obtained and documented

Exclusion Criteria

Excessive body size preventing effective scan of the pancreas as determined by sonographer
Evidence of exocrine pancreatic disease, including pancreatitis, cystic fibrosis, pancreatic adenocarcinoma, or neuroendocrine tumor.
Subjects who are pregnant or breast-feeding
Subjects incapable of giving assent/informed written consent
Known or suspected hypersensitivity to perflutren
Known history or suspected unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) Group 2 (control subjects, part II): Inclusion criteria: No additional inclusion criteria Exclusion criteria:
Diagnosis of diabetes according to the ADA recommended criteria (blood glucose and HbA1c will be measured)
Use of medications used to control high blood sugar (GLP1R agonists, metformin\*, sulfonylureas)
\*Participants taking metformin will be considered eligible if they are willing/able to stop taking the medication for at least two weeks prior to each scan.
Any person who has received immunomodulatory intervention within 3 months of enrollment Group 3 (T1D subjects, part II) Inclusion criteria:
Diagnosis of diabetes according to the ADA recommended criteria (blood glucose and HbA1c will be measured)
Evidence of autoantibodies to at least 1 of the following β-cell autoantigens: insulin, IA-2, GAD65, ZnT8
Presence of insulin autoantibody will only be valid if taken within the first 14 days of diagnosis.
Diagnosis of diabetes within 180 days prior to participation in the study Exclusion criteria:
Use of medications used to control high blood sugar (GLP1R agonists, metformin\*, sulfonylureas)
\*Participants taking metformin will be considered eligible if they are willing/able to stop taking the medication for at least two weeks prior to each scan.
Any person who has received immunomodulatory intervention within 3 months of enrollment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Aurora?

Yes, this clinical trial (NCT05482321) has an active research site in Aurora, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type1diabetes Treatment Options in Aurora, CO

If you're searching for type1diabetes treatment options in Aurora, CO, this clinical trial (NCT05482321) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Aurora research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type1diabetes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type1diabetes clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Aurora, CO

See all pulmonary embolism clinical trials recruiting in Aurora — not just this study.

Browse Pulmonary Embolism Trials in Aurora

Ready to Join in Aurora?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Aurora, CO